Corcept Therapeutics

This early-phase study tests whether the drug miricorilant can lower fat production in the liver for people with MASH, a common liver condition linked to metabolism. Eight participants will take the drug for 6 weeks, and researchers will measure changes in liver fat using scans a…

This study tests a new drug called relacorilant combined with two standard chemotherapy drugs for people with advanced pancreatic cancer that has spread. The goal is to see if the combination can help control the cancer longer and improve survival. About 60 participants will rece…

This study tests a new drug called nenocorilant combined with an immunotherapy (nivolumab) in people with advanced solid tumors that have not responded to standard treatments. The goal is to find the best dose and see if the combination can shrink tumors or slow their growth. Abo…

This study tests an experimental drug, dazucorilant, in 279 adults with ALS. The goal is to see if it can slow the disease's progression and improve muscle strength and breathing. Participants will receive either the drug or a placebo, and researchers will monitor their safety an…

This study tests a drug called relacorilant combined with other treatments for people with ovarian, fallopian tube, peritoneal, or endometrial cancers. About 270 participants will join to see if the combination helps slow cancer growth. The goal is to control the disease, not cur…